Effect of Cholecalciferol Supplementation on CVD, Inflammation, and Bone Metabolism Markers in CKD: A Randomized Double Blind Placebo Controlled Feasibility Trial
Indian Journal of Nephrology · 12.06.2026 · 1-9
DOI: 10.25259/ijn_110_2026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Nephrology, online erschienen am 12.06.2026. Verfasst von Kajal Kamboj und 8 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Background
Vitamin D deficiency is common in CKD and associated with cardiovascular disease (CVD) and bone mineral metabolism. The long-term impact of cholecalciferol supplementation on CVD is unknown. We tested the effects of cholecalciferol supplementation on CVD outcomes [major adverse cardiovascular events (MACE)], progression of CKD, and markers of bone mineral metabolism and inflammation in patients with pre-dialysis CKD. Materials and Methods The study was a single-center, prospective, randomized, placebo-controlled, double blind clinical trial. Patients with CKD, between 18-75 years, estimated glomerular filtration rate 10-45 mL/min/1.73m 2 , serum 25(OH)D levels 20-50 ng/mL were enrolled. Participants received either cholecalciferol 60000 IU once/2 weeks or a matching placebo and followed up at every 3 months till 36 months after enrolment. All clinical, demographic, and biomarker characteristics were analyzed at baseline and at annual follow-up.
Results
692 participants were screened, of which 126 were enrolled. However, 37 participants dropped before randomization. 89 participants were randomized: 46 to the cholecalciferol group and 43 to the placebo group. Both groups were similar with respect to MACE events, need for renal replacement therapy, and all-cause mortality. Over one year, serum 25(OH)D increased in the cholecalciferol group [Mean diff between groups: 31.89, 95% CI: 20.46 to 43.32, p
Zitieren
APA
Kamboj, K., Manoharan, K., Sharma, S., Khera, H., Shafiq, N., Kohli, H. S., Yadav, A. K., Kumar, V., & Jha, V. (2026). Effect of Cholecalciferol Supplementation on CVD, Inflammation, and Bone Metabolism Markers in CKD: A Randomized Double Blind Placebo Controlled Feasibility Trial. Indian Journal of Nephrology, 0, 1-9. https://doi.org/10.25259/ijn_110_2026
Vancouver
Kamboj K, Manoharan K, Sharma S, Khera H, Shafiq N, Kohli HS, et al. Effect of Cholecalciferol Supplementation on CVD, Inflammation, and Bone Metabolism Markers in CKD: A Randomized Double Blind Placebo Controlled Feasibility Trial. Indian Journal of Nephrology. 2026;0:1-9. doi:10.25259/ijn_110_2026
BibTeX
@article{Kamboj2026,
author = {Kamboj, Kajal and Manoharan, Karthikeyan and Sharma, Shubham and Khera, Himanshi and Shafiq, Nusrat and Kohli, Harbir Singh and Yadav, Ashok Kumar and Kumar, Vivek and Jha, Vivekanand},
title = {Effect of Cholecalciferol Supplementation on CVD, Inflammation, and Bone Metabolism Markers in CKD: A Randomized Double Blind Placebo Controlled Feasibility Trial},
journal = {Indian Journal of Nephrology},
year = {2026},
volume = {0},
pages = {1--9},
doi = {10.25259/ijn_110_2026}
}
EUVIMED